Archive
-
2021/07/02The first subject enrolled in the FORWARD research on Furmonertinib-based adjuvant treatment
-
2021/06/30Breaking News! 800 million USD plus equity share
-
2021/06/11Never forget why we started, never stop where we pursue
-
2021/05/09Furmonertinib added to Qindao e-Insurance coverage rolled out on Mother’s Day
-
2021/04/30Allist employees insured under the Shanghai new supplemental medical insurance plan
-
2021/04/24Furmonertinib covered by Zhoushan Supplemental Medical Insurance Program
-
2021/04/18National Kick-off Meeting for FORWARD, a Study Evaluating Furmonertinib as Adjuvant Therapy, Successfully Held
-
2021/04/14Furmonertinib Incorporated into Linyi Medicare Catalogue
-
2021/03/10Allist and BCTC kicks off new partnership eyeing Internet+ medical care innovation
-
2021/03/09The first prescription of Furmonertinib issued in 15 provinces and municipalities across China